Lukas Biomedical (ROCO:6814) Interest Expense : NT$-3.0 Mil (TTM As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Lukas Biomedical Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Lukas Biomedical's interest expense for the six months ended in Jun. 2023 was NT$ -1.6 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-3.0 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Lukas Biomedical's Operating Income for the six months ended in Jun. 2023 was NT$ -11.9 Mil. Lukas Biomedical's Interest Expense for the six months ended in Jun. 2023 was NT$ -1.6 Mil. Lukas Biomedical did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lukas Biomedical Interest Expense Historical Data

The historical data trend for Lukas Biomedical's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lukas Biomedical Interest Expense Chart

Lukas Biomedical Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Interest Expense

-2.56

-5.19

-4.83

-4.42

-2.92

Lukas Biomedical Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Interest Expense	Get a 7-Day Free Trial					-2.09	-2.32	-1.57	-1.35	-1.60

Lukas Biomedical Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-3.0 Mil.

Lukas Biomedical (ROCO:6814) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lukas Biomedical's Interest Expense for the six months ended in Jun. 2023 was NT$-1.6 Mil. Its Operating Income for the six months ended in Jun. 2023 was NT$-11.9 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2023 was NT$90.7 Mil.

Lukas Biomedical's Interest Coverage for the quarter that ended in Jun. 2023 is calculated as

Lukas Biomedical did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Lukas Biomedical (ROCO:6814) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lukas Biomedical Inc (ROCO:6814) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Xinyi Road, Da'an District, 3rd Floor, No. 2, Lane 265, Section 4, Taipei, TWN

Website

https://www.lukas-bio.com.tw

Lukas Biomedical Inc is engaged in the research and development of immunotherapy for cancer treatment technologies. It researches on the Memory T cell (LuLym-T) to improve the clinical outcome of cancer treatment.

Lukas Biomedical (ROCO:6814) Headlines

No Headlines